Gilead Sciences Company Profile (NASDAQ:GILD)

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences declared a quarterly dividend on Tuesday, May 2nd. Shareholders of record on Friday, June 16th will be paid a dividend of $0.52 per share on Thursday, June 29th. This represents a $2.08 annualized dividend and a yield of 3.22%. The ex-dividend date is Wednesday, June 14th. View Gilead Sciences' Dividend History.

Gilead Sciences, Inc. (NASDAQ:GILD) announced its earnings results on Tuesday, May, 2nd. The company reported $2.20 earnings per share for the quarter, topping analysts' consensus estimates of $2.18 by $0.02. The business had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.66 billion. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. View Gilead Sciences' Earnings History.

25 equities research analysts have issued 1 year target prices for Gilead Sciences' shares. Their forecasts range from $65.50 to $100.00. On average, they anticipate Gilead Sciences' share price to reach $81.08 in the next year. View Analyst Ratings for Gilead Sciences.

Here are some recent quotes from research analysts about Gilead Sciences stock:

• 1. According to Zacks Investment Research, "Although Gilead’s first-quarter results beat on earnings, revenues missed expectations. The HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens which now represent 42% of total Gilead HIV prescription volume following the launch of Genvoya and the launches of Odefsey and Descovy in 2016. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales as the company saw a significant uptick in PrEP usage in 2017 with an estimated 125,000 patients using Truvada by the end of the first quarter. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. However, the HCV franchise continues to be under competitive and pricing pressure leading to a massive decline in Harvoni and Sovaldi sales. The company expects that the persistent decline in HCV patient starts will be the primary factor behind the year-over-year decrease." (5/5/2017)
• 2. Maxim Group analysts commented, "Gilead reported 1Q17 results with total revenues of $6.5B, which just missed consensus expectations. Total revenues declined by 11% compared to the prior quarter’s revenues of $7.2B, and product sales were $6.4B, representing a 12% decrease sequentially. HCV product reveneues fell to $2.6B vs. $3.2B in 4Q16, down 20% as a result of declining revenues for Harvoni ($1.4B), Sovaldi ($313M), and Epclusa ($892M)." (5/3/2017)
• 3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)
• 4. Mizuho analysts commented, "We are updating our GILD model post the company's 4Q'16 call. We maintain our Buy rating and lower our PT from $88 to $77 (vs the company's current stock price of $70) to account for the company's 4Q'16 results, 2017 guidance and comments around the HCV business." (3/1/2017)
• 5. Needham & Company LLC analysts commented, "Gilead reported 4Q16 financial results yesterday. Total 4Q16 revenue of $7.32B exceeded our $6.86B and consensus $7.14B estimates, driven by strong Epclusa launch in HCV ($1.05B WW). HCV sales overall, however, continue to fall and mgmt issued 2017 sales guidance below expectations. We remain cautious given revenue trajectory and maintain HOLD." (2/8/2017)

Gilead Sciences saw a decrease in short interest in the month of April. As of April 28th, there was short interest totalling 10,584,715 shares, a decrease of 12.2% from the April 13th total of 12,057,186 shares. Based on an average daily volume of 7,828,032 shares, the days-to-cover ratio is currently 1.4 days. Currently, 0.8% of the company's shares are sold short.

Some companies that are related to Gilead Sciences include Amgen (AMGN), Celgene (CELG), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Illumina (ILMN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), BIO-TECHNE Corp (TECH), Kite Pharma (KITE) and Galapagos NV (GLPG).

Gilead Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.88%), Vanguard Group Inc. (6.94%), State Street Corp (4.59%), Bank of New York Mellon Corp (2.34%), FMR LLC (1.74%) and Parnassus Investments CA (1.28%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Canada Pension Plan Investment Board, NN Investment Partners Holdings N.V., Westfield Capital Management Co. LP, Parametric Portfolio Associates LLC, Waverton Investment Management Ltd, Morgan Stanley and Pioneer Investment Management Inc.. Company insiders that have sold Gilead Sciences stock in the last year include Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton and Paul Rutherford Carter. View Insider Buying and Selling for Gilead Sciences.

Gilead Sciences' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Parnassus Investments CA, Bank of New York Mellon Corp, Renaissance Technologies LLC, Platinum Investment Management Ltd., Los Angeles Capital Management & Equity Research Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Gilead Sciences.

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Gilead Sciences stock can currently be purchased for approximately $64.50.